Artwork

Sisällön tarjoaa Mayo Clinic. Mayo Clinic tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!

Obesity Pharmacotherapy Management

21:18
 
Jaa
 

Manage episode 432805997 series 1324703
Sisällön tarjoaa Mayo Clinic. Mayo Clinic tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

Host: Darryl S. Chutka, M.D. [@chutkaMD]

Guest: Kristina M. Thurber, Pharm D., R.PH.

Obesity in the U.S. is reaching epidemic proportions. Managing our overweight patients has been challenging, with few being able to adopt and adhere to a healthy diet and exercise program. There is a class of medications that improves blood glucose in type 2 diabetics and in most cases also results in significant weight loss. These medications are known as glucagon-like peptide 1 or GLP-1 agonists. A substantial number of patients are taking these medications, some for management of diabetes but for many others, the weight loss they produce. How do these medications work to produce weight loss? How much weight loss can patients expect? How much do they cost and most importantly, are these medications the solution to obesity as a health problem? In this podcast, I’ll be discussing these questions with my guest, Kristina M. Thurber, Pharm D., R.P.H., a pharmacist at the Mayo Clinic as we review “Obesity Pharmacotherapy Management”.

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

  continue reading

553 jaksoa

Artwork

Obesity Pharmacotherapy Management

Mayo Clinic Talks

257 subscribers

published

iconJaa
 
Manage episode 432805997 series 1324703
Sisällön tarjoaa Mayo Clinic. Mayo Clinic tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

Host: Darryl S. Chutka, M.D. [@chutkaMD]

Guest: Kristina M. Thurber, Pharm D., R.PH.

Obesity in the U.S. is reaching epidemic proportions. Managing our overweight patients has been challenging, with few being able to adopt and adhere to a healthy diet and exercise program. There is a class of medications that improves blood glucose in type 2 diabetics and in most cases also results in significant weight loss. These medications are known as glucagon-like peptide 1 or GLP-1 agonists. A substantial number of patients are taking these medications, some for management of diabetes but for many others, the weight loss they produce. How do these medications work to produce weight loss? How much weight loss can patients expect? How much do they cost and most importantly, are these medications the solution to obesity as a health problem? In this podcast, I’ll be discussing these questions with my guest, Kristina M. Thurber, Pharm D., R.P.H., a pharmacist at the Mayo Clinic as we review “Obesity Pharmacotherapy Management”.

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

  continue reading

553 jaksoa

Semua episode

×
 
Loading …

Tervetuloa Player FM:n!

Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.

 

Pikakäyttöopas